NASDAQ · PHARMACEUTICAL PREPARATIONS
Pasithea Therapeutics Corp. KTTA
5 fiscal years on record · USD · FY2025 reported · SEC filings only
$-20.4M
Growth
—
Revenue, FY2025 · full 5-year series below
Revenue $M
Net income $M
FY2022 · Revenue 0.5 · Net income -13.9
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
Operating margin
Net margin
FY2022 · Operating -2587.3% · Net -2864.3%
ROE
FY2025 · ROE -58.4%
Each USD of equity lost 58 cents this year.
The 5-year record
5 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue $B | · | · | · | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Income tax $B | · | · | · | · | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | · | · | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −2.91 | −12.69 | −0.42 | −1.76 | −0.21 |
| Dividend / sh $ | · | · | · | · | · |
| Payout % | · | · | · | · | · |
| ROE % | −58.4 | −72.8 | −48.4 | −29.7 | −4.2 |
| Shares out B | 0.02 | 0.00 | 0.00 | 0.00 | 0.02 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 2 failures in 21 reconciliationsAUDITED
Reconciled in 3 of 19 fiscal years. 73 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente2 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2021